Damora Therapeutics, Inc. (DMRA)

No peers from the Biotechnology ... move in DMRA was company-specific rather than sector-driven. ... Limited earnings history; the prior earnings report saw a negative move of -5.52% on the next day. ... Over the last several months, Damora transitioned into a mutCALR-focused biotech, raising signif…

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23), FiscalAI reports.

But, for DMRA, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't ga…

Damora Therapeutics’ Q1 2026 net loss grew to $27.8M as R&D spending jumped, but cash reached $532.9M after a $295.5M equity raise, funding its mutCALR pipeline.

See the latest Damora Therapeutics Inc Ordinary Shares stock price (DMRA:XNAS), related news, valuation, dividends and more to help you make your investing decisions.